Literature DB >> 19276270

Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.

Cigall Kadoch1, Eduard B Dinca, Ramona Voicu, Lingjing Chen, Diana Nguyen, Seema Parikh, Juliana Karrim, Marc A Shuman, Clifford A Lowell, Patrick A Treseler, C David James, James L Rubenstein.   

Abstract

PURPOSE: The prospect for advances in the treatment of patients with primary central nervous system lymphoma (PCNSL) is likely dependent on the systematic evaluation of its pathobiology. Animal models of PCNSL are needed to facilitate the analysis of its molecular pathogenesis and for the efficient evaluation of novel therapeutics. EXPERIMENTAL
DESIGN: We characterized the molecular pathology of CNS lymphoma tumors generated by the intracerebral implantation of Raji B lymphoma cells in athymic mice. Lymphoma cells were modified for bioluminescence imaging to facilitate monitoring of tumor growth and response to therapy. In parallel, we identified molecular features of lymphoma xenograft histopathology that are evident in human PCNSL specimens.
RESULTS: Intracerebral Raji tumors were determined to faithfully reflect the molecular pathogenesis of PCNSL, including the predominant immunophenotypic state of differentiation of lymphoma cells and their reactive microenvironment. We show the expression of interleukin-4 by Raji and other B lymphoma cell lines in vitro and by Raji tumors in vivo and provide evidence for a role of this cytokine in the M2 polarization of lymphoma macrophages both in the murine model and in diagnostic specimens of human PCNSL.
CONCLUSION: Intracerebral implantation of Raji cells results in a reproducible and invasive xenograft model, which recapitulates the histopathology and molecular features of PCNSL, and is suitable for preclinical testing of novel agents. We also show for the first time the feasibility and accuracy of tumor bioluminescence in the monitoring of a highly infiltrative brain tumor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276270      PMCID: PMC4372389          DOI: 10.1158/1078-0432.CCR-08-2054

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

Review 2.  Primary CNS lymphoma.

Authors:  Fred H Hochberg; Joachim M Baehring; Ephraim P Hochberg
Journal:  Nat Clin Pract Neurol       Date:  2007-01

3.  A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice.

Authors:  M Falcone; A J Rajan; B R Bloom; C F Brosnan
Journal:  J Immunol       Date:  1998-05-15       Impact factor: 5.422

4.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

Authors:  Pedro Farinha; Hamid Masoudi; Brian F Skinnider; Karey Shumansky; John J Spinelli; Karamjit Gill; Richard Klasa; Nicolas Voss; Joseph M Connors; Randy D Gascoyne
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

Review 5.  Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion.

Authors:  Jo A Van Ginderachter; Kiavash Movahedi; Gholamreza Hassanzadeh Ghassabeh; Sofie Meerschaut; Alain Beschin; Geert Raes; Patrick De Baetselier
Journal:  Immunobiology       Date:  2006-07-21       Impact factor: 3.144

Review 6.  Molecular pathogenesis of primary central nervous system lymphoma.

Authors:  Cigall Kadoch; Patrick Treseler; James L Rubenstein
Journal:  Neurosurg Focus       Date:  2006-11-15       Impact factor: 4.047

7.  Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.

Authors:  Igor T Gavrilovic; Adília Hormigo; Joachim Yahalom; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

8.  The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13.

Authors:  J Fukushi; M Ono; W Morikawa; Y Iwamoto; M Kuwano
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

9.  Growth and survival mechanisms associated with perineural invasion in prostate cancer.

Authors:  Gustavo E Ayala; Hong Dai; Michael Ittmann; Rile Li; Michael Powell; Anna Frolov; Thomas M Wheeler; Timothy C Thompson; David Rowley
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

10.  Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.

Authors:  M Dancescu; M Rubio-Trujillo; G Biron; D Bron; G Delespesse; M Sarfati
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  21 in total

1.  Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.

Authors:  Seung-Myoung Son; Sang-Yun Ha; Hae-Yong Yoo; Dongryul Oh; Seok-Jin Kim; Won-Seog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-09-30       Impact factor: 7.842

2.  Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics.

Authors:  S Donnou; C Galand; C Daussy; L Crozet; W H Fridman; C Sautès-Fridman; S Fisson
Journal:  Clin Exp Immunol       Date:  2011-06-10       Impact factor: 4.330

3.  Bioluminescence imaging of invasive intracranial xenografts: implications for translational research and targeted therapeutics of brain tumors.

Authors:  Eduard B Dinca; Ramona V Voicu; Alexandru V Ciurea
Journal:  Neurosurg Rev       Date:  2010-07-23       Impact factor: 3.042

4.  Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.

Authors:  Leslie L Muldoon; Seth J Lewin; Edit Dósa; Dale F Kraemer; Michael A Pagel; Nancy D Doolittle; Edward A Neuwelt
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

5.  A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement.

Authors:  Rosa Bosch; María José Moreno; Rebeca Dieguez-Gonzalez; María Virtudes Céspedes; Alberto Gallardo; Manuel Trias; Albert Grañena; Jorge Sierra; Isolda Casanova; Ramon Mangues
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

6.  Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Miaoxia He; Changjing Zuo; Jianjun Wang; Jianmin Liu; Binghua Jiao; Jianmin Zheng; Zailong Cai
Journal:  Neuro Oncol       Date:  2013-03-12       Impact factor: 12.300

Review 7.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

8.  Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.

Authors:  Cigall Kadoch; Jing Li; Valerie S Wong; Lingjing Chen; Soonmee Cha; Pamela Munster; Clifford A Lowell; Marc A Shuman; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2013-11-04       Impact factor: 12.531

Review 9.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

Review 10.  Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.

Authors:  Rym Ben Abdelwahed Bagga; Sabrina Donnou; Jérémie Cosette; Catherine Sautès-Fridman; Mahjoub Aouni; Sylvain Fisson
Journal:  J Neurooncol       Date:  2014-10-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.